Core Insights - AirSculpt Technologies, Inc. (AIRS) reported a quarterly loss of $0.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.01, marking a 300.00% earnings surprise [1] - The company generated revenues of $34.99 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 12.73% and down from $42.55 million year-over-year [2] - AirSculpt Technologies has outperformed the S&P 500 with a 102.1% increase in share price since the beginning of the year, compared to the S&P 500's 14.3% gain [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is breakeven on revenues of $39.44 million, while for the current fiscal year, it is -$0.01 on revenues of $162.93 million [7] - The estimate revisions trend for AirSculpt Technologies was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Technology Services industry, to which AirSculpt Technologies belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Docebo Inc. reported quarterly earnings of $0.34 per share, exceeding the Zacks Consensus Estimate of $0.33 per share, and showing an increase from $0.27 per share a year ago, resulting in an earnings surprise of +3.03% [1] - The company achieved revenues of $61.62 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.90% and up from $55.43 million year-over-year [2] - Docebo has outperformed consensus EPS estimates three times in the last four quarters and has topped consensus revenue estimates four times in the same period [2] Financial Performance - The earnings report indicates a significant improvement in earnings per share compared to the previous year, with a surprise of +45% in the prior quarter [1] - The current consensus EPS estimate for the upcoming quarter is $0.35, with expected revenues of $61.43 million, and for the current fiscal year, the estimate is $1.19 on revenues of $240.05 million [7] Market Position - Docebo shares have underperformed the market, losing about 45.6% since the beginning of the year, while the S&P 500 has gained 14.3% [3] - The Zacks Industry Rank places the Internet - Software sector in the top 30% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] Future Outlook - The sustainability of Docebo's stock price movement will depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current Zacks Rank for Docebo is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]

Core Insights - Coherus Oncology reported a quarterly loss of $0.33 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.32, and a significant decline from a loss of $0.01 per share a year ago, indicating a negative earnings surprise of -3.13% [1] - The company generated revenues of $11.57 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 5.23% and down from $70.77 million in the same quarter last year [2] - Coherus Oncology's stock has increased by approximately 13.4% year-to-date, underperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The earnings outlook for Coherus Oncology is uncertain, with current consensus EPS estimates at -$0.30 for the upcoming quarter and -$1.31 for the current fiscal year, alongside expected revenues of $14.26 million and $56.71 million respectively [7] - The company currently holds a Zacks Rank of 3 (Hold), suggesting that its shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Coherus Oncology belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Coherus Oncology's stock performance [5]

分组1 - AMN Healthcare Services reported quarterly earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.19 per share, but down from $0.61 per share a year ago, resulting in an earnings surprise of +105.26% [1] - The company achieved revenues of $634.5 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.15%, although this is a decrease from year-ago revenues of $687.51 million [2] - AMN Healthcare has consistently surpassed consensus EPS estimates over the last four quarters, indicating a strong performance trend [2] 分组2 - Despite the positive earnings report, AMN Healthcare shares have declined approximately 13.8% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] - The company's earnings outlook is critical for investors, with current consensus EPS estimates at $0.13 for the upcoming quarter and $1.08 for the current fiscal year, alongside revenues of $613.36 million and $2.58 billion respectively [7] - The Zacks Industry Rank places the Medical Services sector in the bottom 40% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

Core Insights - Vasta Platform Limited reported a quarterly loss of $0.07 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, marking an earnings surprise of -40.00% [1] - The company generated revenues of $45.82 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 8.61%, but showing an increase from $39.71 million year-over-year [2] - The stock has increased approximately 146.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.38 on revenues of $150.15 million, while for the current fiscal year, the estimate is $0.33 on revenues of $342.94 million [7] - The estimate revisions trend for Vasta Platform was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Schools industry, to which Vasta Platform belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Legacy Education Inc., another company in the same industry, is expected to report quarterly earnings of $0.15 per share, reflecting a year-over-year decline of 28.6%, with revenues anticipated to be $18.34 million, up 30.9% from the previous year [9][10]

Core Insights - Veritone, Inc. reported a quarterly loss of $0.08 per share, better than the Zacks Consensus Estimate of a loss of $0.11, and improved from a loss of $0.19 per share a year ago, resulting in an earnings surprise of +27.27% [1] - The company achieved revenues of $29.12 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.81% and showing a year-over-year increase from $21.99 million [2] - Veritone shares have increased approximately 104% year-to-date, significantly outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The future performance of Veritone's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $33.32 million, and for the current fiscal year, it is -$0.54 on revenues of $108.39 million [7] Industry Context - The Technology Services industry, to which Veritone belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

分组1 - ICU Medical reported quarterly earnings of $2.03 per share, exceeding the Zacks Consensus Estimate of $1.54 per share, and showing an increase from $1.59 per share a year ago, resulting in an earnings surprise of +31.82% [1] - The company achieved revenues of $533.3 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.66%, although this represents a decline from year-ago revenues of $580.07 million [2] - Over the last four quarters, ICU Medical has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has underperformed, losing about 17.9% since the beginning of the year, compared to the S&P 500's gain of 15.6% [3] - The current consensus EPS estimate for the upcoming quarter is $1.66 on revenues of $527.85 million, and for the current fiscal year, it is $7.03 on revenues of $2.19 billion [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 40% of over 250 Zacks industries, which may negatively impact stock performance [8]

分组1 - Concentra Group reported quarterly earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.37 per share, and showing an increase from $0.37 per share a year ago, resulting in an earnings surprise of +5.41% [1] - The company achieved revenues of $572.8 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.31%, and up from $489.64 million year-over-year [2] - Concentra has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed the market, losing about 3.2% since the beginning of the year, while the S&P 500 gained 15.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.25 on revenues of $532.44 million, and for the current fiscal year, it is $1.32 on revenues of $2.15 billion [7] - The Medical Services industry, to which Concentra belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - Farmer Brothers reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.09, marking an earnings surprise of -111.11% [1] - The company's revenues for the quarter ended September 2025 were $81.6 million, missing the Zacks Consensus Estimate by 4.34% and down from $85.07 million a year ago [2] - Farmer Brothers has underperformed the market, with shares down about 2.2% year-to-date compared to the S&P 500's gain of 15.6% [3] Financial Performance - Over the last four quarters, Farmer Brothers has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $91.5 million, and for the current fiscal year, it is -$0.44 on revenues of $354.5 million [7] Industry Context - The Food - Natural Foods Products industry, to which Farmer Brothers belongs, is currently in the bottom 8% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Farmer Brothers' stock performance [5][6]

Core Insights - Alector reported a quarterly loss of $0.34 per share, better than the Zacks Consensus Estimate of a loss of $0.42, marking an earnings surprise of +19.05% [1] - The company generated revenues of $3.26 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 24.19%, but down from $15.34 million year-over-year [2] - Alector's stock has underperformed, losing approximately 33.6% since the beginning of the year, while the S&P 500 has gained 15.6% [3] Financial Performance - Over the last four quarters, Alector has surpassed consensus EPS estimates four times and topped revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $3 million, and for the current fiscal year, it is -$1.57 on revenues of $17.15 million [7] Industry Context - Alector operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 41% of over 250 Zacks industries [8] - The industry’s performance can significantly impact Alector's stock performance, with research indicating that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of Alector's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The estimate revisions trend for Alector was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6]